The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.
Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.
Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.
Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.
Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin improved pCR vs chemotherapy alone in patients with esophageal squamous cell carcinoma.
Durvalumab plus neoadjuvant FLOT improved pCR vs chemotherapy alone in patients with resectable gastric and GEJ cancers, irrespective of region.
Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.
Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.
ASKB589 demonstrated anti-tumor activity in combination with capecitabine and oxaliplatin plus sintilimab in gastric or gastroesophageal junction cancers.
Real-world findings demonstrated a favorable survival benefit with nivolumab plus chemotherapy in advanced gastroesophageal adenocarcinoma.
Camidanlumab tesirine was well tolerated as a monotherapy and elicited responses when given with pembrolizumab in patients with advanced solid tumors.
Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.
Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.
Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.
Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.
Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.
The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.
Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.
A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.
A coformulation of vibostolimab and pembrolizumab with or without docetaxel failed to result in a statistically significant improvement in progression-free survival compared with docetaxel alone in patients with metastatic non–small cell lung cancer.
Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
The majority of patients with relapsed CLL treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation at the time of disease progression, indicating that these mutations may not be the primary drivers of resistance and relapse in this population.
Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.
DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.
The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.
Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.